Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth.
This trial is active, not recruiting.
|Conditions||pulpotomies primary teeth, effectiveness of medcem mta® in pulpotomies primary teeth|
|Treatment||medcem mta pulpotomies in primary teeth.|
|Sponsor||Hadassah Medical Organization|
|Start date||October 2013|
|End date||October 2018|
|Trial size||60 participants|
|Trial identifier||NCT01962077, Nathalie- HMO-CTIL|
assess the effect of MedCem MTA as a pulp medicament following pulpotomy in human primary molars with carious pulp exposure in comparison to Formocresol.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Success of MedCem MTA pulpotomy in primary molar
time frame: Up to 36 mon
Male or female participants from 2 years up to 10 years old.
Inclusion Criteria: 1. healthy children 2. with Asymptomatic primary molars with a deep carious lesion; 3. Exposure of a vital pulp by caries; 4. No clinical or radiographic evidence of pulp degeneration, such as excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction,swelling, or sinus tract; 5. Ability to perform a leakage free restoration of the teeth using stainless steel crown, or amalgam/resin based restoration.
|Official title||Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth|
Call for more information